Metal homeostasis is a critical physiological process that maintains the delicate balance of transition metals—copper, zinc, and iron—within the brain. These metals are essential cofactors for numerous enzymatic reactions, neurotransmitter synthesis, and cellular respiration. However, dysregulation of metal homeostasis is increasingly recognized as a key pathological mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)[1].
The brain presents unique challenges for metal regulation due to the blood-brain barrier, high metabolic demand, and the presence of metal-binding proteins involved in aggregation-prone proteins like amyloid-beta (Abeta) and alpha-synuclein (a-syn)[2]. This page provides a comprehensive integration of copper, zinc, and iron homeostasis mechanisms and their roles in neurodegeneration.
The brain requires precise regulation of metal ions:
Copper enters neurons through the copper transporter CTR1 (SLC31A1) and is distributed by the copper chaperone ATOX1 to target proteins including ATP7A and ATP7B[3].
| Protein | Function | Brain Expression |
|---|---|---|
| CTR1 (SLC31A1) | Copper uptake transporter | High in choroid plexus, neurons |
| ATOX1 | Copper chaperone | Cytosolic, universal |
| ATP7A | Cu-exporting ATPase | Neurons, vascular endothelium |
| ATP7B | Cu-exporting ATPase | Liver, astrocytes |
| CCS | Copper chaperone for SOD1 | Motor neurons, cortex |
In AD, copper binding to amyloid-beta (Abeta) promotes aggregation and toxicity. Copper-Abeta complexes generate reactive oxygen species (ROS) through Fenton-like reactions [4]:
Copper homeostasis is also disrupted in AD, with elevated copper in amyloid plaques and altered ATP7A/ATP7B expression [5].
In PD, copper deficiency in the substantia nigra may contribute to dopaminergic neuron loss. Copper is a cofactor for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis. Additionally, copper can bind to alpha-synuclein and promote its aggregation [6].
Zinc homeostasis is maintained by two families of zinc transporters [7]:
| Transporter | Function | Brain Region |
|---|---|---|
| ZIP1, ZIP3 | Zinc uptake | Hippocampus, cortex |
| ZnT1 | Zinc efflux | Neuronal membranes |
| ZnT5, ZnT6 | Golgi zinc transport | Synaptic vesicles |
| ZnT10 | Zinc efflux | Basal ganglia |
Zinc serves as a synaptic neurotransmitter and neuromodulator. Synaptic zinc is released from presynaptic vesicles during neuronal activity and modulates NMDA receptor function, GABAergic signaling, and synaptic plasticity [8].
Zinc plays complex roles in Abeta metabolism:
Zinc dysregulation contributes to alpha-synuclein aggregation and dopaminergic neuron vulnerability. Elevated zinc levels in the substantia nigra of PD patients may promote oxidative stress and mitochondrial dysfunction [10].
Iron homeostasis is tightly regulated by proteins controlling import, export, storage, and sensing [11]:
| Protein | Function | Role in Neurodegeneration |
|---|---|---|
| Transferrin (TF) | Iron transport | Elevated in CSF of AD/PD |
| Transferrin Receptor 1 (TFR1) | Iron import | Upregulated in degenerating neurons |
| Ferroportin (FPN) | Iron export | Reduced in PD substantia nigra |
| Ferritin (FTH1/FTL) | Iron storage | Elevated in iron accumulation disorders |
| DMT1 | Divalent metal transport | Increased in substantia nigra in PD |
| Hepcidin (HAMP) | Ferroportin regulator | Dysregulated in AD and PD |
Iron accumulation in the brain is a hallmark of AD:
The iron-responsive element binding protein 2 (IREB2/IRP2) regulates iron metabolism genes and is implicated in AD pathogenesis.
Iron accumulation in the substantia nigra pars compacta (SNc) is one of the earliest pathological findings in PD:
NBIA disorders feature excessive brain iron accumulation due to mutations in genes including:
All three metals can generate oxidative stress through Fenton chemistry:
Fenton reaction: Fe2+ + H2O2 -> Fe3+ + OH- + OH* (hydroxyl radical)
Copper Fenton-like: Cu+ + H2+ -> Cu2+ + OH- + OH*
This produces hydroxyl radicals (OH*), the most reactive ROS species, causing [14]:
Chelating agents can remove excess metals and reduce oxidative stress [15]:
| Agent | Target Metals | Clinical Status |
|---|---|---|
| Deferoxamine (DFO) | Iron | Phase II for AD/PD |
| Deferiprone | Iron | Phase II for PD |
| Clioquinol | Copper, Zinc | Phase II for AD |
| PBT2 | Copper, Zinc | Phase II for AD |
| CuATSM | Copper | Phase I for ALS |
Copper ionophores like CuATSM (Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone)) deliver copper to cells and may restore mitochondrial function [16].
Zinc supplementation has shown cognitive benefits in some AD trials, though timing and dosage are critical.
Copper, zinc, and iron homeostasis are interconnected:
Que EL, et al. The roles of metals in neurodegenerative diseases. Nat Rev Neurol. 2015. ↩︎
Toth K, et al. Metal homeostasis in neurodegenerative diseases. J Alzheimers Dis. 2022. ↩︎
Lutsenko S, et al. Function and regulation of human copper-transporting ATPases. Physiol Rev. 2023. ↩︎
Barnham KJ, Bush AI. Metals in Alzheimer's and Parkinson's disease. Curr Opin Chem Biol. 2024. ↩︎
Squitti R, et al. 'Copper in Alzheimer''s disease: from meta-analyses to therapeutic strategies'. J Alzheimers Dis. 2023. ↩︎
Wang J, et al. 'Copper and alpha-synuclein: a dangerous liaison in Parkinson''s disease'. Nat Rev Neurol. 2024. ↩︎
Kambe T, et al. Zinc homeostasis and signaling in health and diseases. Nat Rev Nephrol. 2025. ↩︎
Sensi SL, et al. Zinc in the physiology and pathology of the central nervous system. Nat Rev Neurosci. 2024. ↩︎
Corona C, et al. Zinc dyshomeostasis in Alzheimer's disease. J Alzheimers Dis. 2022. ↩︎
Chen L, et al. 'Zinc and Parkinson''s disease: molecular mechanisms and therapeutic potential'. Nat Rev Neurol. 2025. ↩︎
Lane DJR, et al. Cellular iron metabolism in health and disease. Nat Rev Hematol. 2024. ↩︎
Ward RJ, et al. 'Iron and the brain: new insights into Alzheimer''s disease'. Nat Rev Neurol. 2024. ↩︎
Devos D, et al. 'Targeting iron in Parkinson''s disease: a promising therapeutic strategy'. Nat Rev Neurol. 2024. ↩︎
Halliwell B. Role of free radicals in the neurodegenerative diseases. Free Radic Biol Med. 2023. ↩︎
Ritchie CW, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta and metal pathology in Alzheimer's disease. Nat Rev Drug Discov. 2023. ↩︎
McFarland NR, et al. CuATSM for the treatment of amyotrophic lateral sclerosis. Nat Rev Neurol. 2024. ↩︎